What is Scholar Rock?
Scholar Rock operates at the intersection of advanced disease biology and therapeutic development. By focusing on the molecular mechanisms underlying serious diseases, the company has established itself as a key player in the biopharmaceutical sector. Its business model is predicated on translating groundbreaking research into clinical-stage assets, positioning the firm as a high-potential innovator within the life sciences landscape. The company's strategic focus remains on developing novel treatment approaches that offer meaningful improvements for patients suffering from chronic and debilitating conditions, supported by a sophisticated network of long-term institutional partners.
How much funding has Scholar Rock raised?
Scholar Rock has raised a total of $726M across 8 funding rounds:
Series A
$20M
Series B
$36M
Series C
$47M
Stock Offering
$86.3M
Stock Offering
$51.8M
Debt
$50M
Stock Offering
$230M
Stock Offering
$205M
Series A (2014): $20M with participation from Timothy Springer, EcoR1 Capital, ARCH Ventures, The Kraft Group, and Polaris Partners
Series B (2016): $36M led by Timothy Springer, EcoR1 Capital, The Kraft Group, Polaris Partners, ARCH Venture Partners, Cormorant Asset Management, and Fidelity Management and Research Company
Series C (2018): $47M supported by Fidelity Management and Research Company, Cormorant Asset Management, Polaris Partners, The Kraft Group, Invus, ARCH Venture Partners, Timothy Springer, EcoR1 Capital, and Redmile Group
Stock Issuance/Offering (2018): $86.3M featuring Undisclosed
Stock Issuance/Offering (2019): $51.8M backed by Undisclosed
Debt (2020): $50M with participation from Oxford Finance and Silicon Valley Bank
Stock Issuance/Offering (2020): $230M led by Undisclosed
Stock Issuance/Offering (2022): $205M, investors not publicly disclosed
Key Investors in Scholar Rock
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs.
Polaris Partners
A venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, providing coaching and resources for long-term growth.
EcoR1 Capital
A San Francisco-based investment fund focused on the biotech sector, dedicated to advancing therapeutic innovation and supporting breakthroughs in biological discovery.
What's next for Scholar Rock?
Looking ahead, the recent capital injection provides Scholar Rock with the necessary runway to accelerate its clinical development programs and expand its research capabilities. As the company transitions through its current lifecycle stage, the focus will likely shift toward scaling its operational infrastructure and advancing its lead candidates through pivotal trials. By leveraging its strong balance sheet and the expertise of its seasoned investor base, Scholar Rock is well-positioned to navigate the complexities of the regulatory environment and move closer to commercializing its therapeutic pipeline, ultimately aiming to deliver value to both patients and stakeholders in the global healthcare market.
See full Scholar Rock company page
